Seladelpar
Showing 1 - 7 of 7
Primary Biliary Cholangitis Trial in United States (Seladelpar 10 mg, Placebo)
Recruiting
- Primary Biliary Cholangitis
- Seladelpar 10 mg
- Placebo
-
Lancaster, California
- +4 more
Sep 26, 2023
Primary Biliary Cholangitis Trial in United States (Seladelpar 10 mg, Placebo)
Recruiting
- Primary Biliary Cholangitis
- Seladelpar 10 mg
- Placebo
-
Chandler, Arizona
- +3 more
Oct 2, 2023
NASH - Nonalcoholic Steatohepatitis Trial in United States (Seladelpar, Placebos)
Terminated
- NASH - Nonalcoholic Steatohepatitis
- Seladelpar
- Placebos
-
Glendale, Arizona
- +13 more
Aug 30, 2022
Primary Sclerosing Cholangitis Trial in Canada, Poland, United States (Seladelpar, Placebo to match Seladelpar)
Completed
- Primary Sclerosing Cholangitis
- Seladelpar
- Placebo to match Seladelpar
-
San Francisco, California
- +9 more
Jun 1, 2021
Primary Biliary Cholangitis Trial in Worldwide (Seladelpar 10 mg, Placebo, Seladelpar 5 mg)
Active, not recruiting
- Primary Biliary Cholangitis
- Seladelpar 10 mg
- +2 more
-
Chandler, Arizona
- +128 more
Jan 27, 2023
Hepatic Impairment Trial in United States (seladelpar)
Completed
- Hepatic Impairment
- seladelpar
-
Lakewood, Colorado
- +3 more
May 17, 2018
Primary Biliary Cirrhosis (PBC) Trial in Worldwide (Placebo Comparator, Experimental: Seladelpar / MBX-8025 50 mg, Experimental:
Terminated
- Primary Biliary Cirrhosis (PBC)
- Placebo Comparator
- +2 more
-
Phoenix, Arizona
- +48 more
Jan 25, 2018